Welcome to the Division of Nuclear Medicine at Duke University Hospital.
The division of nuclear medicine includes general nuclear medicine, nuclear cardiology, PET/CT, and the Duke Radiopharmacy. The division provides the clinical service for Duke University Hospital, Duke Raleigh Hospital, and the Durham VA Medical Center, including radionuclide diagnostic imaging studies in general nuclear medicine, PET/CT, and nuclear cardiology; laboratory based exams, such as quantitative glomerular filtration rate studies; and radionuclide therapy.
General nuclear medicine studies include a wide variety of adult and pediatric planar and SPECT/CT imaging, such as bone scans, renal scans, HIDA scans, ventilation/perfusion lung scans, parathyroid scans, MIBG scans, and pre-surgical sentinel lymph node scintigraphy.
The division is unique in providing cardiovascular stress testing and myocardial perfusion imaging within nuclear medicine. The nuclear medicine faculty includes two cardiologists who oversee the Duke Nuclear Cardiology Program, facilitating a close working relationship with the Duke Internal Medicine division of cardiology. Cardiac PET/CT imaging is also available for myocardial perfusion imaging and for F-18 FDG metabolic imaging for evaluation of myocardial viability and cardiac sarcoidosis.
The PET/CT center is very active, providing diagnostic imaging service for patients with known or suspected illnesses, such as malignancy, dementia and infection, and for patients with intractable seizures. Available clinical PET radiopharmaceuticals include F-18 FDG, Ga-68 DOTATATE (neuroendocrine tumors), and F-18 fluciclovine (prostate cancer).
The division provides comprehensive therapeutic nuclear medicine service, working closely with the Duke Endocrinology service for I-131 therapy for hyperthyroidism and thyroid cancer, and the Duke Oncology service for Ra-223 Xofigo therapy for bone metastases, Y-90 Zevalin therapy for lymphoma, I-131 MIBG and Lu-177 DOTATATE (Lutathera) therapies for neuroendocrine tumors. Y-90 microsphere therapy is also provided in collaboration with the Interventional Radiology division for primary and metastatic hepatic tumors. Integral to the therapeutic nuclear medicine program is the close working relationship with our Cyclotron/Radiochemistry faculty and staff, Radiopharmacy, and the Duke Radiation Safety office.
The division is also very active in research; the Nuclear Cardiology Program has one of the largest cardiovascular and nuclear cardiology databases from a single academic institution in the U.S.A., from which outcome research studies can be generated. Other research activities include participation in the National Clinical Trials Network toward development of multi-center oncology trials. There is also active research in PET/CT and SPECT/CT instrumentation working closely with physicists in the nuclear medicine division and faculty members from the Duke Graduate Program in Medical Physics.
The division is committed to teaching the multiple facets of nuclear medicine, including topics of clinical imaging techniques and image interpretation, radionuclide therapy, instrumentation, nuclear medicine physics and radiopharmacy to medical students, diagnostic radiology residents, nuclear medicine residents, nuclear radiology fellows, and pharmacy students. Teaching is done in an informal setting of daily image read out sessions and weekly case conferences by the nuclear medicine faculty and in a formal setting of weekly didactic lectures by physicians from the nuclear medicine faculty and from radiation safety, physicists, radiopharmacists and nuclear medicine technologists.